AT A GLANCE
07/18/2023

Coronavirus Disease 2019 (COVID-19)

Updated weekly on Tuesdays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content .................................................................................................................................................. 3
Public Health Agencies ................................................................................................................................. 3
  Public Health Agency of Canada | canada.ca ......................................................................................... 3
  BC Centre for Disease Control | bccdc.ca ..................................................................................... 3
  Institut national de santé publique | ......................................................................................... 3
  CDC: Centers for Disease Control and Prevention | cdc.gov .......................................................... 3
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu ........................................ 4
  FDA: U.S. Food & Drug Administration | fda.gov ......................................................................... 4
  Public Health England | gov.uk ............................................................................................................. 4
  World Health Organization | who.int ........................................................................................................ 4
  Other relevant government bodies / health care organizations ................................................................. 5
  Center for Infectious Disease Research Policy | cidrap.umn.edu ......................................................... 5
  National Collaborating Centre for Environmental Health | ncceh.ca .......................................................... 6
  COVID-END | www.mcmasterforum.org/networks/covid-end ..................................................................... 6
  ProMED | promedmail.org ..................................................................................................................... 6

Updated Daily ............................................................................................................................................... 6
  COVID-19 resources (case counts) | arcgis.com ..................................................................................... 6
  COVID-19 Canada Open Data Working Group | COVID-19 CODWG .................................................... 6
  Johns Hopkins CCSE | systems.jhu.edu ................................................................................................ 6
  NextStrain | nextstrain.org .................................................................................................................... 6

Guidelines and Technical documents (updated regularly) ............................................................................ 6
Section I: General Guidelines .................................................................................................................... 6
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- COVID-19 activity levels [updated 07-18-2023]
- Key COVID updates [07-18-2023]
  o Weekly change in cases: 1,070
  o Total cases: 4,693,798
  o Weekly change in deaths: 9
  o Total deaths: 53,063
  o Weekly tests reported: 19,084
  o Weekly percent positivity: 5.8%
- An Advisory Committee Statement (ACS); National Advisory Committee on Immunization (NACI). Guidance on the use of COVID-19 vaccines in the fall of 2023 [07-11-2023]
- Summary of National Advisory Committee on Immunization (NACI) statement of July 11, 2023 [07-11-2023]
- COVID-19 daily epidemiology update [updated regularly]

BC Centre for Disease Control | bccdc.ca
- COVID-19 care [last updated 03-27-2023]

Institut national de santé publique | inspq.qc.ca
- Proportion de la population ayant augmenté sa consommation d’alcool au cours de la pandémie de COVID-19 et facteurs associés [07-18-2023]
- Vigie de la COVID-19 dans les services de garde éducatifs à l’enfance - Mai 2023 [07-18-2023]
- Évaluation de l’expérience du traçage, de l’isolement et de la gestion des contacts par les cas positifs à la COVID-19 [07-17-2023]
- Prélèvements alternatifs à l’écouvillonnage nasopharyngé pour la détection du SRAS-CoV-2 [07-04-2023]

CDC: Centers for Disease Control and Prevention | cdc.gov
- Stay up to date with COVID-19 vaccines [updated 07-17-2023]
- COVID Data Tracker [updated 07-17-2023]
  Key Data Takeaways
  o COVID-19 indicators, including emergency department visits, test positivity, and wastewater levels, have begun to show small increases nationally.
  o Hospital admissions have leveled off after steadily declining.
- Information for laboratories about coronavirus (COVID-19) [updated 07-13-2023]
- Health departments: information on COVID-19 [updated 07-06-2023]
By the end of week 27 (ending 9 July 2023), decreasing or stable trends were observed in EU/EEA all indicators based on pooled country data for COVID-19 in all age groups. This is a continuation of the pattern observed in recent weeks.

Of 17 countries reporting COVID-19 cases, one showed an increase in overall case rates compared to the previous week. One country reported an increase in ICU occupancy. There were 81 deaths reported from 12 countries, with one country reporting an increase in its COVID-19 death rate.

No country is predicted to see increases in the number of reported COVID-19 cases, hospital admissions, or deaths in the period up to 23 July 2023, based on ensemble model forecasts.

Among the nine countries reporting at least 10 results from SARS-CoV-2 sequencing or genotyping for weeks 25–26 (19 June to 2 July 2023), the estimated distribution of variants of concern (VOC) or of interest (VOI) was 92.9% (87.5–100.0% from nine countries) for XBB.1.5, 4.9% (0.7–7.7% from six countries) for BA.2.75, 2.3% (0.5–10.0% from four countries) for XBB and 1.0% (1.0–1.0% from one countries) for BQ.1.

There aren’t any updates in the cumulative vaccine uptake in the EU/EEA comparing to the previous week. Among people aged 60 years and older, the cumulative uptake of a first booster was 84.9% (country range: 13.3–100.0%) and of a second booster was 35.6% (country range: 0.4–87.0%).

SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non-systematic literature review for surveillance purposes [07-12-2023]

FDA: U.S. Food & Drug Administration | fda.gov

FDA roundup: July 14, 2023 [07-14-2023]
FDA updates duration of enforcement discretion policies in two COVID-19 era FSMA guidances [07-13-2023]
Coronavirus (COVID-19) update: daily roundup [updated regularly]

Public Health England | gov.uk
Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”
Location of Public Health England (PHE) functions from 1 October 2021

World Health Organization | who.int
Global Health Workforce responses to address the COVID-19 pandemic: what policies and practices to recruit, retain, reskill, and support health workers during the COVID-19 pandemic should inform future workforce development? [07-18-2023]
Childhood immunization begins recovery after COVID-19 backslide [07-18-2023]
• **Weekly epidemiological update on COVID-19 - 13 July 2023** [07-13-2023]
• **WHO coronavirus (COVID-19) dashboard** [updated regularly]

### Other relevant government bodies / health care organizations

- **Canadian Centre for Occupational Health and Safety**
  - COVID-19 health and safety resources [updated regularly]

- **UK Health Security Agency**
  - COVID-19: paediatric surveillance [updated 07-18-2023]

- **UK Medicines and Healthcare products Regulatory Agency**
  - How tests and testing kits for coronavirus (COVID-19) work [updated 07-17-2023]

- **UK Office for Health Improvement and Disparities**
  - COVID-19: migrant health guide [updated 07-12-2023]

- **UK Office for National Statistics**
  - Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 10 July 2023 [07-10-2023]
  - COVID-19 and Respiratory Infection Survey, symptoms and impact, UK: 10 July 2023 [07-10-2023]
  - COVID-19 and Respiratory Infection Survey (CRIS): Quality and Methodology Information (QMI) [07-10-2023]

- **UK Department for Transport**
  - Our changing travel – how people’s travel choices are changing [07-06-2023]

  Study of the travel behaviour of people in England following the COVID-19 pandemic and during a period of rising cost of living.

### Center for Infectious Disease Research Policy | cidrap.umn.edu

- 'Hybrid' prenatal care not tied to worse maternal, newborn health amid COVID-19 [07-18-2023]
- COVID-19 vaccine tied to reduced deaths in seniors with dementia [07-17-2023]
- Only 1 in 5 US nursing home residents given monoclonal antibodies, antivirals for COVID [07-17-2023]
- Early indicators hint at US COVID-19 uptick [07-14-2023]
- Report: Hospitals may have received too much COVID relief [07-14-2023]
- Ambulance personnel felt high stress during pandemic [07-13-2023]
- COVID vaccine boosters protect cancer patients from poor outcomes, study suggests [07-13-2023]
- Emergency visits for cannabis in youth, young adults increased in pandemic [07-13-2023]
- Global COVID markers continue to decline [07-13-2023]
- More emergency visits for teen girls' mental health seen during second year of pandemic [07-12-2023]
- GAO releases recommendations aimed at future pandemics [07-12-2023]
- Studies describe pandemic's lasting influence on children [07-11-2023]
- Report details COVID-19 spillover events in white-tailed deer [07-11-2023]
- Quick takes: COVID vaccine ordering cutoff, destroying chemical weapons, new CDC head takes reins [07-11-2023]
National Collaborating Centre for Environmental Health | ncceh.ca

- June 2023 research scan [06-21-2023]
- May 2023 research scan with COVID-19 sections [05-18-2023]
- April 2023 research scan with COVID-19 sections [04-19-2023]

COVID-END | www.mcmasterforum.org/networks/covid-end

- Global spotlight 27.1: key additions for March 2023 [03-30-2023]
- Global spotlight 26.1: key additions for February 2023 [02-28-2023]

ProMED | promedmail.org

- Latest on COVID-19 [individual posts]
- COVID-19 update (26): animal, North America, wild deer as reservoirs [07-13-2023]

Updated Daily

COVID-19 resources (case counts) | arcgis.com

- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG

- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu

- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org

- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated regularly)

The guidelines listings are current to 04-12-2023; posted 04-18-2023

Section I: General Guidelines

Ontario / Canada Main Page

- Ontario guidance
- Canadian guidance (federal)
Reopening/Rebuilding Guidelines

Ontario
- ON Coronavirus Disease 2019 (COVID-19): [updated 03-09-2022]

Canada (federal) and provinces and territories (other than Ontario)
- CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
- CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 02-11-2023]
- AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB Manitoba Pandemic Response System [no date]
- QC Coronavirus disease (COVID-19) in Québec [updated 04-03-2023]
- NB Living with COVID-19 [no date]
- NL NL life with COVID-19 [no date]
- PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
- NS Government’s response to COVID-19 [updated regularly]
- NW COVID-19 [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut's Path: living with COVID-19 [no date]
- National Collaborating Centre for Indigenous Health (NCCIH): Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
- Implementation guidance for assessments of frontline service readiness [07-01-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [03-30-2023]

ECDC
- Conducting after-action reviews of the public health response to COVID-19: update [03-21-2023]
- Data on country response measures to COVID-19 [08-25-2022]
- Transitioning beyond the acute phase of the COVID-19 pandemic: approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]
- Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations - General

Ontario Ministry of Health
- COVID-19 vaccine-relevant information and planning resources [updated 03-01-2023]

Canada (Federal)
• Guidance on COVID-19 vaccine booster doses: initial considerations for 2023 [updated 02-07-2023]
• Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration [12-21-2022]
• Archived 39: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines [updated 10-07-2022]
• Planning guidance for immunization clinics for COVID-19 vaccines [updated 03-06-2023]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-22-2022]
• Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [06-29-2022]
• Summary of NACI statement of June 29, 2022 [06-29-2022]
• Adjusting public health measures in the context of COVID-19 vaccination [06-27-2022]
• Health care provider vaccine tool kit. version 3 [06-10-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Initial guidance on a second booster dose of COVID-19 vaccines in Canada [04-05-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• COVID-19 drugs and vaccines [updated 09-16-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)
• BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 03-27-2023]
• BC COVID-19 vaccine eligibility [updated 03-27-2023]
• BC Vaccine SOP: cold chain incident reporting process [updated 03-24-2023]
• BC Novavax shipping, storage and use guidelines [03-24-2023]
• BC Novavax redistribution guidelines [03-24-2023]
• BC Pfizer pediatric vaccine shipping, storage, thawing and use guidelines (orange/maroon cap) [updated 03-07-2023]
• BC Spikevax™ (Moderna) [updated 03-00-2023]
• BC COVID-19 vaccine screening checklist [03-00-2023]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [02-00-2023]
- BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [12-09-2022]
- BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [03-00-2022]
- BC 2021/22 seasonal influenza vaccine eligibility [08-00-2022]
- BC Immunization manual appendix A: informed consent (page 4) [07-00-2022]
- BC Moderna redistribution guidelines [07-20-2022]
- BC Janssen shipping, storage and use guideline [06-15-2022]
- BC Immunization manual: summary of changes: admin circular [03-04-2022]
- BC Point of care risk assessment (PCRA) [no date]
- BC Janssen redistribution guidelines [01-17-2022]
- BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
- BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
- BC Administrative circular [12-31-2021]
- BC Latex content in vaccines [10-00-2021]
- BC Pfizer vaccine sub dose vial reporting [07-13-2021]
- BC Cold chain assets warranty contact information [05-20-2021]
- BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO

- WHO SAGE roadmap on uses of COVID-19 vaccines in the context of OMINCORN and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity [03-30-2023]
- Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [updated 02-07-2023]
- Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [updated 02-07-2023]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [10-27-2022]
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [08-18-2022]
- Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [06-06-2022]
- COVID-19 and mandatory vaccination: ethical considerations and caveats [05-30-2022]
- COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.3 [04-21-2022]
- Injection safety in the context of coronavirus disease (COVID-19) vaccination: addendum to policy brief, 5 April 2022 [04-05-2022]
- Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19v [03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
- NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
- COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
- Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
- Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
- Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
- Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
- Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
- Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
- AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
- AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
- Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
- COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
- Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
- Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
- Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC

- Stay up to date with COVID-19 vaccines including boosters [updated 03-31-2023]
• Understanding how COVID-19 vaccines work [02-03-2023]
• COVID-19 vaccine safety reporting systems [updated 12-01-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [09-23-2022]
• COVID-19 vaccination program operational guidance [08-11-2022]
• COVID-19 vaccination clinical & professional resources [05-13-2022]
• Communication resources for COVID-19 vaccines [updated 12-11-2021]
• Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol [no date]
• Interim guidance for routine and influenza immunization services during the COVID-19 pandemic [04-15-2021]
• Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
• National protocol for COVID-19 vaccine (adults) [updated 04-03-2023]
• COVID-19 vaccination: what to expect after vaccination [updated 04-06-2023]
• COVID-19 vaccination programme [updated 04-03-2023]
• COVID-19 vaccination: vaccine product information [03-31-2023]
• COVID-19: the green book, chapter 14a [03-09-2023]
• COVID-19 vaccination: information for healthcare practitioners [10-10-2022]
• Monitoring reports of the effectiveness of COVID-19 vaccination [09-01-2022]
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [04-01-2022]
• National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [04-01-2022]
• National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [04-01-2022]
• COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]
• COVID-19 vaccination: booster dose resources [02-02-2022]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]
• Monitoring of the effectiveness of COVID-19 vaccination [09-14-2021]
• COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC
• Interim public health considerations for COVID-19 vaccination roll-out during 2023 [04-05-2023]
• COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 04-03-2023]
• Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – third update [modified 03-16-2023]
• Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA, [updated 03-03-2023]
• Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines [07-11-2022]
• Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose [04-28-2022]
• Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
• Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
• Infographic: facilitating COVID-19 vaccination acceptance and uptake [10-15-2021]
• Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]

Australia
• COVID-19 booster vaccine advice [updated 04-05-2023]
• Clinical recommendations for COVID-19 vaccines [updated 03-21-2023]
• ATAGI clinical guidance for COVID-19 vaccine providers [updated 02-17-2023]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination [08-31-2022]
• COVID-19 vaccination – vaccine dose policy [updated 07-13-2022]
• COVID-19 vaccination – updated provider kit for general practices [12-14-2021]

Vaccinations - Specific populations

Canada (Federal)
• Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration [12-09-2022]
• Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding [archived] [09-09-2022]
• Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [07-14-2022]
• Summary of NACI statement of July 14, 2022: • Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [07-14-2022]
• NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [archived] [06-29-2022]
• NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [archived] [06-29-2022]
- NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [archived] [03-17-2022]
- Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

- BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022 [06-10-2022]
- BC Residential care COVID–19 vaccination status [02-28-2022]

WHO

- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-26-2021]
- Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
- Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC

- COVID-19 vaccines while pregnant or breastfeeding [10-20-2022]
- Resources to promote the COVID-19 vaccine for children & teens [09-13-2022]
- COVID-19 vaccines for people who would like to have a baby [07-14-2022]
- COVID-19 vaccine information for specific groups [06-19-2022]
- COVID-19 vaccine equity for racial and ethnic minority groups [03-29-2022]
- Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [01-20-2022]
- Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]

UK

- COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [updated 01-10-2023]
- COVID-19 vaccination: resources for children aged 5 to 11 years [03-28-2022]
- COVID-19 vaccination: resources for children and young people aged 12 to 17 years [02-01-2022]
- COVID-19 vaccination: guide for adults [01-19-2022]
- Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
- Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
- COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
- Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Vaccinations- Adverse Effects

Canada (Federal)
- Reporting ocular adverse events following COVID-19 vaccination: Communiqué to healthcare professionals (May 30, 2022) [05-30-2022]
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]

CDC
- Reported adverse events [updated 03-07-2023]
- COVID-19 vaccine side effects in children and teens [09-14-2022]
- Possible side effects after getting a COVID-19 vaccine [09-14-2022]
- Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [09-02-2022]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]

WHO
- Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) [03-00-2023]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [10-27-2022]
Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [06-00-2022]

PHAC
- COVID-19 case report form [updated 11-21-2022]

CDC
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
- WHO COVID-19 Case definition [updated 07-22-2022]
- Revised case report form for confirmed novel coronavirus COVID-19 (report to WHO within 48 hours of case identification) [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]
- COVID-19: background information [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 12-09-2022]
Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2023]

PHAC
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [modified 02-22-2023]
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [07-05-2022]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [03-24-2022]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC
- Using antibody tests for COVID-19 [updated 12-16-2022]
- Information for laboratories about coronavirus (COVID-19) [11-09-2022]
- Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [updated 07-17-2022]
- Testing strategies for SARS-CoV-2 [05-05-2022]
- How to report COVID-19 laboratory data [04-04-2022]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
• **Evaluation for SARS-CoV-2 testing in animals** [03-30-2022]
• **Guidance for reporting SARS-CoV-2 sequencing results** [03-21-2022]
• **Guidance for general laboratory safety practices during the COVID-19 pandemic** [03-02-2022]
• **Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)** [12-13-2021]
• **Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]
• **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [08-09-2021]
• **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [06-30-2021]
• **Variants and genomic surveillance for SARS-CoV-2** [04-02-2021]

**UK**

• **Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [11-22-2022]
• **National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests** [11-22-2022]
• **Technical validation protocol for SARS-CoV-2 nucleic acid detection** [11-22-2022]
• **Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [11-22-2022]
• **How tests and testing kits for coronavirus (COVID-19) work** [10-07-2022]
• **NHS test and trace statistics (England): methodology** [05-18-2022]
• **COVID-19: guidance for sampling and for diagnostic laboratories** [03-29-2021]

**ECDCC**

• **The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates** [05-10-2021]

**Australia**

• **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [01-28-2022]

**Miscellaneous Guidelines**

**PHAC**

• **COVID-19 and people with disabilities in Canada** [updated 01-30-2023]
• **Individual public health measures** [updated 01-27-2023]
• **Summary of evidence supporting COVID-19 public health measures** [updated 01-27-2023]
• **Federal/provincial/territorial public health response plan for ongoing management of COVID-19** [04-08-2022]

**Canadian provinces and territories (other than Ontario)**

• **BC COVID-19 ethical decision-making framework** [12-24-2020]
WHO

- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [updated 03-30-2023]
- Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
- Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
- ACT-Accelerator 'fair share asks' - by country [02-09-2022]
- WHO technical consultation on oxygen access scale-up for COVID-19 [no date]
- Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]

CDC

- Domestic travel during COVID-19 [updated 08-24-2022]
- Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [09-23-2022]
- Wildfire smoke and COVID-19 [08-02-2022]
- RRT composition: COVID-19 considerations [03-01-2021]

ECDC

- One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
- Behavioural insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]

Other

- Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance

Canada

- COVID-19 data trends [modified 03-06-2023]
- Mathematical modelling and COVID-19 [modified 04-01-2022]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO

- Environmental surveillance for SARS-CoV-2 to complement public health surveillance – Interim Guidance [04-14-2022]
- WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [02-15-2022]
- End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
- **Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States** [01-21-2022]

**CDC**
- **COVID-19 serology surveillance** [03-11-2021]
- **Data visualization** [02-16-2021]
- **Large-scale geographic seroprevalence surveys** [10-02-2020]

**ECDC**
- **Organisation of vector surveillance and control in Europe** [12-13-2021]
- **Surveillance of COVID-19 in long-term care facilities in the EU/EEA** [11-29-2021]
- **Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30)** [11-29-2021]
- **COVID-19 variants: genomically confirmed case numbers** [11-29-2021]
- **Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA** [11-26-2021]
- **COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens** [10-18-2021]
- **Guidance for representative and targeted genomic SARS-CoV-2 monitoring** [05-03-2021]

**UK**
- **COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools** [09-04-2020]

**Variants – Omicron**

**Canada**
- **SARS-CoV-2 variants: national definitions, classifications and public health actions** [08-18-2022]

**CDC**
- **What is genomic surveillance?** [updated 12-02-2022]

**UK**
- **Investigation of SARS-CoV-2 variants** [updated 03-10-2023]
- **SARS-CoV-2 variants of public health interest** [updated 03-10-2023]

**ECDC**
- **Methods for the detection and characterisation of SARS-CoV-2 variants – second update** [08-02-2022]
- **Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA** [06-13-2022]
- **Technical guidance for antigenic SARS-CoV-2 monitoring** [06-27-2022]
- **Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update** [01-27-2022]
- **Threat assessment brief: implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update** [12-02-2021]
- **Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00)** [11-30-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states [01-21-2022]

Testing

Canada
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [09-08-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario Version 15.2 [03-27-2023]
- COVID-19 provincial testing guidance. Version 15.3 [01-25-2023]
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing. Version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening. Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]

Canadian provinces and territories (other than Ontario)
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]

WHO
- Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC
- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [updated 12-20-2022]
- Using antibody tests for COVID-19 [updated 12-16-2022]
- Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities [11-29-2022]
- CDC's diagnostic test for COVID-19 only and supplies [11-14-2022]
- CDC's influenza SARS-CoV-2 multiplex assay [11-14-2022]
- Overview of testing for SARS-CoV-2 (COVID-19) [09-28-2022]
- Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [09-23-2022]
- Testing strategies for SARS-CoV-2 [05-05-2022]
• **Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community** [04-04-2022]
• **Guidance for SARS-CoV-2 point-of-care and rapid testing** [04-04-2022]
• **Nucleic acid amplification tests (NAATs)** [06-14-2021]
• **Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings** [03-29-2021]

**UK**
• **Investigation of SARS-CoV-2 variants: technical briefings** [updated 02-10-2023]
• **SARS-CoV-2 variants of public health interest** [updated 02-10-2023]
• **Investigation of SARS-CoV-2 variants of concern: variant risk assessments** [updated 12-12-2022]
• **How tests and testing kits for coronavirus (COVID-19) work** [10-07-2022]
• **SARS-CoV-2 variant of concern diagnostic assurance** [04-14-2022]
• **Testing for coronavirus (COVID-19) before hospital** [03-08-2022]
• **Coronavirus COVID-19 serology and viral detection tests: technical validation reports** [updated 02-18-2022]
• **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021** [07-16-2021]
• **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021** [07-16-2021]
• **SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence** [10-16-2020]

**ECDC**
• **Methods for the detection and identification of SARS-CoV-2 variants- first update** [08-02-2022]
• **A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control** [04-27-2022]
• **Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise** [04-27-2022]
• **Considerations for the use of antibody tests for SARS-CoV-2 – first update** [02-10-2022]
• **Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories** [12-20-2021]
• **Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK** [10-26-2021]
• **Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings** [05-06-2021]
• **Considerations for the use of saliva as sample material for COVID-19 testing** [05-03-2021]
• **Considerations on the use of self-tests for COVID-19 in the EU/EEA** [03-17-2021]
• **Guidance for COVID-19 quarantine and testing of travellers** [03-12-2021]
• **Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA** [02-16-2021]
• **Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update** [02-15-2021]
• **COVID-19 testing strategies and objectives** [09-18-2020]
- Objectives for COVID-19 testing in school settings [08-10-2020]

Australia
- PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [06-20-2022]
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment
Canada
- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [06-22-2022]
- COVID-19 for health professionals: treatments [02-01-2022]
- Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [updated 03-27-2023]
- COVID-19 patient screening guidance document version 5.0 [08-26-2021]

BC
- Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 01-10-2023]
- Pathway for treatment of mild-moderate COVID-19 treatment [no date]
- Therapy in adult pregnant patients with COVID-19 [updated 09-07-2022]

WHO
- WHO living guideline: drugs to prevent COVID-19 [updated 03-24-2023]
- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-09-2023]
- Clinical care information for COVID-19 [updated 01-30-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- If you are sick or caring for someone [11-29-2022]
- Ending isolation and precautions for people with COVID-19: interim guidance [08-31-2022]
- Understanding Risk [08-11-2022]
- Clinical care quick reference for COVID-19 [03-16-2022]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

WHO
- Therapeutics and COVID-19 [07-14-2022]
- COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
- COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]
- Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
- Hypertension and COVID-19 [06-17-2021]
- WHO information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
- WHO COVID-19 clinical care bundle [04-23-2021]
- Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH
- COVID-19 treatment guidelines [updated 03-06-2023]

UK
- Find help and support if you have long COVID [updated 03-29-2023]
- COVID-19: migrant health guide [03-08-2022]

Australia
- Coronavirus (COVID-19) – identifying the symptoms [12-09-2022]
COVID-19 Diagnosis in Children

Canada

WHO
- A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus [02-16-2023]

CDC
- Information for Pediatric Healthcare Providers [02-10-2023]

Other
- American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [02-08-2023]
- BC Children with immune compromise [08-02-2022]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition

Canada
- Post COVID-19 condition (long COVID) [modified 03-09-2023]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2022]
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Post COVID-19 condition [12-16-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Post-COVID conditions; CDC Science [updated 03-31-2023]
- Post-COVID conditions: information for healthcare providers [12-16-2022]

UK
- Long-term effects of coronavirus (long COVID) [reviewed 03-21-2023]

Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [01-30-2023]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2022]

WHO
- **Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance** [02-17-2022]

**CDC**
- **Isolation and precautions for people with COVID-19** [03-21-2023]
- **Quarantine and isolation** [03-21-2023]
- **Global contact tracing** [01-24-2023]
- **Contact tracer’s interview tool: notifying people about an exposure to COVID-19** [02-28-2022]
- **Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview** [02-28-2022]
- **Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions** [02-28-2022]
- **Contact tracing for COVID-19** [02-10-2022]

**UK**
- **COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191]** [03-29-2023]
- **People with symptoms of a respiratory infection including COVID-19** [06-10-2022]

### Infection Prevention and Control

**PHAC / Health Canada**
- **At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19** [01-27-2023]
- **Coronavirus disease (COVID-19): prevention and risks** [01-27-2023]
- **COVID-19 mask use: advice for community settings** [01-30-2023]
- **Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance** [07-22-2022]
- **COVID-19: Guidance on indoor ventilation during the pandemic** [07-05-2022]
- **Federal/provincial/territorial public health response plan for ongoing management of COVID-19** [04-08-2022]
- **Infection prevention and control for COVID-19: interim guidance for home care settings** [01-25-2022]
- **Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021** [12-24-2021]

**Ontario**
- **COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0** [06-10-2022]

**Canadian provinces and territories (other than Ontario)**
- **BC COVID-19: outbreak management protocol for acute care settings** [08-22-2022]

**WHO**
- **Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023** [01-13-2023]
• WHO policy brief: maintaining infection prevention and control measures for COVID-19 in health care facilities, 14 September 2022 [09-14-2022]
• WHO COVID-19 infection prevention and control (IPC) pillar achievements. February 2020 – January 2021 [05-14-2021]
• Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC
• Cleaning and disinfecting your facility: every day and when someone is sick [11-02-2022]
• Use and care of masks [09-09-2022]

UK
• Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [08-02-2022]
• Designated standards: PPE [02-17-2023]

ECDC
• Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]

Other
• BC Infection prevention and control guidance for community immunization clinics [09-28-2022]
• BC The hierarchy for infection prevention and exposure control measures for communicable diseases [06-29-2022]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health
• Management of cases and and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
• COVID-19 guidance: acute care v.9 [01-11-2023]
• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canada
• COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

BC
• Student practice education guideline for health care settings during the COVID-19 pandemic [01-25-2023]

WHO
• COVID-19 home care bundle for health care workers [02-09-2022]
• Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
• Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]

CDC
• Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-23-2022]
• Staff shortages [09-23-2022]

UK
• COVID-19: managing healthcare staff with symptoms of a respiratory infection [03-31-2023]

ECDC
• Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]
• Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]
• The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health
• COVID-19 guidance document for long-term care homes in Ontario [04-03-2023]
• COVID-19 guidance: long-term care homes and retirement homes for public health units Version 10 [03-31-2023]
• COVID-19 screening tool for long-term care homes and retirement homes: version 13 [08-31-2022]
• Ministry for seniors and accessibility COVID-19 guidance document for retirement homes in Ontario [06-24-2022]

PHAC
• Infection prevention and control for COVID-19: interim guidance for long term care homes [01-25-2022]
• COVID-19: guidance on pets and long-term care homes [07-20-2021]
• Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
• COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO
• Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC
• Correctional and detention facilities [11-29-2022]
• **Investigating cases in homeless shelters** [11-29-2022]
• **Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities** [11-29-2022]
• **Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments** [09-15-2022]
• **Interim infection prevention and control recommendations for healthcare personnel during the Coronavirus disease 2019 (COVID-19) pandemic** [09-23-2022]
• **Interim guidance for general population disaster shelters during the COVID-19 pandemic** [08-30-2021]

**UK**
• **Acute respiratory illness, including flu and COVID-19 in prisons** [04-06-2023]
• **Infection prevention and control in adult social care: COVID-19 supplement** [04-06-2023]
• **COVID-19: outbreaks in prisons, refuges and other higher-risk accommodation settings** [04-04-2023]
• **Operating principles for night shelters** [08-31-2022]
• **Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1** [02-18-2022]
• **Infection control in prisons and places of detention** [07-01-2011]

**Other**
• CSC Testing of inmates in federal correctional institutions for COVID-19 [04-12-2023]

**Section III: Guidelines for the Community**

**Travel, Transport & Borders**

**Ontario Ministry of Health**
• **Travelling during COVID-19** [01-27-2023]

**Canada**
• **Travel advice and advisories by destination** [updated often]
• **COVID-19: travel, testing and borders** [04-03-2023]

**CDC**
• **COVID-19 travel recommendations by destination** [updated regularly]
• **Stay up to date with your COVID-19 vaccines including Boosters** [04-06-2023]
• **Requirement for proof of COVID-19 vaccination for air passengers** [12-30-2022]

**UK**
• **COVID-19: guidance for people whose immune system means they are at higher risk** [03-14-2023]
• **People with symptoms of a respiratory infection including COVID-19** [06-10-2022]
• **Coronavirus (COVID-19): cruise ship travel** [03-17-2022]

**Schools / Childcare**

**Ontario Ministry of Health**
• **Management of cases and contacts of COVID-19 in Ontario version 15.2** [03-27-2023]
Mental Health/Substance Use Health

Ontario Ministry of Health


PHAC

- Helping people who use substances [10-01-2022]

Provinces & Territories (excluding Ontario)

- QC The roles of public health in population mental health and wellness promotion [10-03-2022]
- QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
- QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
- QC Public health ethics and COVID-19: selected resources [11-00-2021]

WHO

- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]
- Rise, respond, recover: renewing progress on women’s, children’s and adolescent’s health in the era of COVID-19 [12-00-2021]
- Social isolation and loneliness among older people: advocacy brief [07-29-2021]
- Smoking and COVID-19 [06-30-2020]
- Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
- COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

**SAMHSA**
- Community engagement: an essential component of an effective and equitable substance use prevention system [11-00-2022]
- Disaster planning handbook for behavioural health service programs [03-00-2021]
- From crisis to care: building from 988 and beyond for better mental health outcomes [09-00-2022]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

**UK**
- Alcohol and drug misuse prevention and treatment guidance [03-07-2022]
- Every Mind Matters: looking after your mental health [no date]
- Domestic abuse: how to get help [02-17-2023]

**Community/Workplaces**

**Ontario Ministry of Health**
- Protection from COVID-19 and other respiratory illnesses [04-12-2023]
- COVID-19 and workplace health and safety [03-09-2023]
- COVID-19 and your employment standards protections [06-26-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

**PHAC**
- Summary of evidence supporting COVID-19 public health measures [01-27-2023]
- Community based public health measures [01-27-2023]
- How businesses and employees can stay safe while operating during COVID-19 [01-27-2023]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [01-30-2023]
- COVID-19 mask use: advice for community settings [01-30-2023]

**WHO**
- The generic all-hazards risk assessment and planning tool for mass gathering events [01-12-2023]
- Preventing and mitigating COVID-19 at work [05-19-2021]

**CDC**
- Specific settings [12-07-2022]
- Use and care of masks [09-09-2022]
- Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

**UK**
• Infection prevention and control in adult social care: COVID-19 supplement [04-04-2023]
• Living safely with respiratory infections, including COVID-19 [06-16-2022]
• Reducing the spread of respiratory infections, including COVID-19, in the workplace [06-10-2022]
• Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]
• Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]

Other
• CCOHS daycares [07-14-2022]